Dr. McVicar’s career in the pharmaceutical industry spans more than 30 years in research and development as a team leader and C-suite executive. He has held numerous high ranking positions, leading teams at Sandoz, Novartis, RPR Gencell, Sepracor, Innotek Pharmaceuticals, Flex Pharma, and Salarius Pharmaceuticals. During his career, Dr. McVicar personally oversaw the development of multiple drug candidates from early testing to approval, including BROVANA®, XOPENEX MDI®, and XOPENEX’s pediatric approval. Dr. McVicar has raised well over $100 million in venture financing, led numerous licensing transactions, and has successfully executed the merger of Flex and Salarius Pharmaceuticals, where he remains Chair of the Board of Directors. He is an author of numerous peer-reviewed scientific publications and an inventor on 15 issued U.S. patents. Dr. McVicar earned his B.S. in chemistry from SUNY College at Oneonta and his Ph.D. in chemistry from the University of Vermont.